Embracing the New Era of Immunotherapy in Gastric Cancer Treatment
Advanced gastric cancer still presents a grim outlook, typically yielding a median survival rate of approximately 12 to 15 months. Recently, immune checkpoint inhibitors have emerged as a promising standard treatment for various malignancies, including advanced gastric cancer. They have shown signif...
發表在: | South African Gastroenterology Review |
---|---|
主要作者: | |
格式: | Article |
語言: | English |
出版: |
In House Publications
2024
|
在線閱讀: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85214072146&partnerID=40&md5=8b3ce2a276384e92041ff8b98c24a144 |